Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The company advances a pipeline of late stage clinical product candidates, including setrusumab for osteogenesis imperfecta, alvelestat for severe alpha 1 antitrypsin deficiency associated lung disease, and vantictumab for autosomal dominant osteopetrosis type 2. It also holds earlier stage assets such as leflutrozole and navicixizumab, which have been outlicensed to partners. Mereo’s strategy involves acquiring derisked candidates from larger pharmaceutical firms and advancing them through clinical development with the goal of securing regulatory approval and eventual commercialization. To date, the company has completed large randomized Phase 2 trials for four of its product candidates and the Phase 1b portion of a Phase 1b/2 for a fifth candidate, demonstrating meaningful clinical progress. Collaborations with Ultragenyx provide funding and manufacturing support for the global development of setrusumab, while partnerships with Feng Biosciences and Āshibio have enabled the outlicensing of navicixizumab and vantictumab respectively.

Mereo generates revenue primarily through upfront payments, milestone payments, and royalty receipts from licensing and collaboration agreements with partners. To date, the company has received a $50 million upfront fee and a $9 million milestone from Ultragenyx for setrusumab, $4 million and a $2 million milestone from Feng Biosciences for navicixizumab, and a $1 million upfront fee plus a $0.5 million milestone from ReproNovo for leflutrozole. Additionally, Mereo has obtained payments from Āshibio related to the outlicensing of vantictumab. The company has not yet generated any revenue from product sales because none of its candidates have received regulatory approval. These nondilutive funding sources provide essential cash to support ongoing research and development activities while preserving shareholder capital.

Within the rare disease biotechnology sector, Mereo occupies a niche position as a specialized developer of orphan designated therapies that have already attracted significant prior investment. The company’s competitive advantages stem from the regulatory benefits attached to its assets, including orphan drug designations from the European Commission and the U. S. Food and Drug Administration, PRIME designation from the European Medicines Agency, Breakthrough Therapy and rare pediatric disease designations from the FDA, and Fast Track designation for alvelestat. These designations, combined with partnerships that provide funding and expertise, allow Mereo to advance candidates more efficiently than many early stage peers. Furthermore, the company leverages the substantial preclinical, clinical and manufacturing data packages that accompanied the acquired assets, reducing development risk and timelines.

Mereo’s current collaborators and potential customers include Ultragenyx, Feng Biosciences, Āshibio, ReproNovo, Novartis, and AstraZeneca, with whom it has entered into licensing, collaboration, or supply agreements. Once its product candidates receive regulatory approval, the company anticipates serving patients, physicians, and healthcare systems that treat rare diseases such as osteogenesis imperfecta, alpha 1 antitrypsin deficiency associated lung disease, and autosomal dominant osteopetrosis type 2. In addition, payers and reimbursement authorities in key markets represent important future customers for any approved therapies. As of September 30, 2025, Mereo reported an accumulated deficit of $493.7 million, reflecting its continued investment in research and development.